The Immune Tolerance Network (ITN) is a collaborative network for clinical research focused on the development of therapeutic approaches for asthma and allergy, autoimmune diseases, type 1 diabetes and solid organ transplantation that lead to immune tolerance. These tolerogenic approaches aim to reprogram the immune system so that disease-causing immune responses are stopped while maintaining the immune system’s ability to combat pathogen infection.
The ITN is funded by a grant from the National Institute of Allergy and Infectious Disease of the National Institutes of Health awarded to the Benaroya Research Institute (Seattle, WA), in partnership with the University of California San Francisco and Duke University.
The ITN develops, funds and conducts mechanistic, laboratory-based studies in conjunction with clinical trials through collaborations with academic, governmental and industry researchers. For more information about the ITN and other clinical trials, please visit immunetolerance.org.